GENBGenerate Biomedicines, Inc.
$13.86
$13.86
$11.2152 weeks$20.40
Price
End-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for GENB today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$2.10B
1 yearn/a
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
Generate Biomedicines, Inc. (GENB) reported revenue of $6.3M in Q2 2026 (quarter ended Jun 30, 2026), down 28% from the same quarter a year earlier. That came with net loss of $67M. The next results filing is expected around Nov 5, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 7, 2026Generate Biomedicines, Inc.Earnings release · press release
- Mar 2, 2026As previously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-293204) (the “Registration Statement”), of Generate Biomedicines, Inc. (the “Company”), and in connection with the completion of the initial public offering of the Company’s common stock (the “IPO”), the Company filed its …Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry